Product Introduction
Bioactivity


英文名: IACS-13909

描述: IACS-13909 (BBP-398) 是具有口服活性的、选择性的 SHP2变构抑制剂，其 IC50=15.7 nM，Kd=32 nM。与其他磷酸酶相比，它对 SHP2的选择性更高。它能够抑制受体酪氨酸激酶 (RTK)/MAPK 途径的信号传导，并具有抗癌作用。

体外活性: IACS-13909有效地抑制了携带多种激活型RTKs作为癌基因驱动因素的肿瘤细胞的增殖。

体内活性: 在具有EGFR依赖性及EGFR独立性抗药机制的EGFR变异型奥希替尼耐药的非小细胞肺癌(NSCLC)模型中，IACS-13909作为单药或与奥希替尼联合应用，有效抑制了体外肿瘤细胞增殖，并在体内导致了肿瘤退缩。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 9 mg/mL (23.86 mM)


关键字: antiproliferative | RTK | inhibit | IACS 13909 | SHP2 | pMEK | anticancer | Inhibitor | MAPK | BBP 398 | BBP398 | pERK | IACS-13909 | Phosphatase | IACS13909

相关产品: PTP1B-IN-1 | EWP 815 | Tegeprotafib | MP07-66 | Methyl orsellinate | JMS-053 | KY-226 | Rosiptor | (-)-p-Bromotetramisole Oxalate | Aloe-emodin-8-O-β-D-glucopyranoside

相关库: Drug Repurposing Compound Library | Glycometabolism Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Phosphatase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Active Compound Library